Cipla's Q2 FY27 operating performance was in line with its expectation, although the high base of gRevlimid sales last year continued to weigh on reported performance, says the brokerage.
Cipla's Q2 FY27 operating performance was in line with its expectation, although the high base of gRevlimid sales last year continued to weigh on reported performance, says the brokerage.
<iframe src="https://hindustansphere.com/embed/cluster/fa9ee04309b3f22248a1c476fdadad80558e4bb2" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Cipla Q2 Results Review: ICICI Securities Remains Bullish After Inline Numbers; Check Target Price"></iframe>
